A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
Latest Information Update: 05 Mar 2025
At a glance
- Drugs LY 4006896 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 28 Feb 2025 Planned End Date changed from 1 May 2028 to 1 Nov 2027.
- 28 Feb 2025 Planned primary completion date changed from 1 May 2028 to 1 Nov 2027.
- 28 Feb 2025 Status changed from not yet recruiting to recruiting.